Article

Surgeon recommends firms manufacture IOLs in 0.25 D steps

It would be helpful if IOL manufacturers made lenses available in 0.25 D steps and provided more detailed information regarding the optical design since refractive outcomes can now be predicted more accurately.

It would be helpful if IOL manufacturers made lenses available in 0.25 D steps and provided more detailed information regarding the optical design since refractive outcomes can now be predicted more accurately, according to Thomas Olsen from the University Eye Clinic, Aarhus Hospital, Denmark.

Dr Olsen obtained the refractive results from several thousand IOL implantations using optical biometry and compared them with the predictions made using regression methods, thick lens vergence methods and exact ray tracing methods. In each case the predictions were based on previously described true ACD-prediction algorithms.

It was discovered that thick lens vergence and exact ray tracing methods are more effective than regression methods and that refractive outcomes can be predicted accurately well below 0.5 D, which is the current power availability step.

The results indicate that it would be useful if IOLs were available in 0.25 D steps.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.